Laurus Labs Ltd - Share Price
LAURUSLABS
Laurus Labs LtdFinancials
Laurus Labs LtdNews & Updates
Board of Laurus Labs recommends Interim Dividend
Oct 30,2020 10:07 AM
Of Rs.0.8 per share
Laurus Labs fixes record date for interim dividend Oct 30,2020
Laurus Labs consolidated net profit rises 328.42% in the September 2020 quarter Oct 29,2020
Laurus Labs fixes record date for interim dividend Oct 29,2020
Laurus Labs schedules board meeting Oct 19,2020
Laurus Labs hits the roof ahead of record date for stock split Sep 28,2020
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Ltd | 2,387.55 | 0.00 | 33,019.97 | 32.52 | 0.25 | 2,414.45 | 275.13 |
| Dr Lal Pathlabs Ltd | 2,322.30 | 97.99 | 19,118.06 | 79.90 | 0.52 | 404.30 | 136.20 |
| Laurus Labs Ltd | 292.05 | 26.49 | 15,546.53 | 237.59 | 0.17 | 1,127.30 | 41.36 |
| Metropolis Healthcare Ltd | 2,270.00 | 89.97 | 11,434.89 | 52.36 | 0.35 | 242.55 | 115.55 |
| Fortis Healthcare Ltd | 142.55 | 330.81 | 10,739.28 | 4.15 | 0.00 | 153.13 | 117.90 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Laurus Labs LtdSummary & Reports
Laurus Labs is a leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (P... More
Registered Office
Plot No 21 Jawaharlal Nehru,Pharma City Parawada,Visakhapatnam, Andhra Pradesh,531021
Tell. : +91-891-3061222
Website : http://www.lauruslabs.com
Email : secretarial@lauruslabs.com
Registrar Office
Karvy Selenium Tow-B, Nanakramguda, Hyderabad-500032 INDIA
Tell. : +91-40-67162222
Website : www.kfintech.com
Email : einward.ris@kfintech.com
Reports by laurus-labs-ltd
Latest Release by laurus-labs-ltd
Result Express
Laurus Labs Ltd's Q3FY19 consolidated net profit declines 48.9% yoy to Rs17.82cr : Misses Estimates
Nov 24, 2020 10:11 AM
The company’s consolidated revenue stood at Rs529.46cr, up 10.55% yoy but down 10% qoq.
Shareholding Snapshot
Loading ...
| Sep - 2020 | |
|---|---|
| Promoter | - |
| Foreign | 0.00% |
| Indian | 32.12% |
| Total Promoter | 32.12% |
| Non Promoter | - |
| Institutions | 27.08% |
| Non-Institutions | 40.79% |
| Total Non-Promoter | 67.88% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Dividend
Annc. Date
29 Oct 2020
Effective. Date
10 Nov 2020
Divi. Type
Interim
Divi.(%)
40
Divi. Amt.
0.8
The Board of Directors of the Company in their meeting held on October 29, 2020 have approved for th... More
Purpose
Board Meeting
Exp. Date
29 Oct 2020
Annc. Date
19 Oct 2020
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is schedul... More
Purpose
Split
Annc. Date
30 Apr 2020
Old FV
New FV
2
Ex-Split Date
29 Sep 2020
Outcome of Board Meeting for April 30, 2020Trading Members of the Exchange are hereby informed that ... More
Jun 12, 2017
